Meglumine

Meglumine

SCHEMBL724392

CNC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TACR1TTRgyrAgyrBparCparE

The experimentally established mechanism targets of Meglumine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 1.00
LMNA P02545 2/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
TDP1 Q9NUW8 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.49
PDE4A P27815 1/20 0.41
USP2 O75604 1/20 0.38
SLCO1B1 Q9Y6L6 1/20 0.38
CYP1A2 P05177 1/20 0.34
TSHR P16473 1/20 0.34
HIF1A Q16665 1/20 0.34
TOP1 P11387 1/20 0.33
SLC6A2 P23975 2/20 0.32
SLC6A4 P31645 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Meglumine SCHEMBL18270062 1.00 KDM4E (1.00) KDM4ELMNAL3MBTL1TDP1SMN1; SMN2
Meglumine SCHEMBL14126374 1.00 KDM4E (1.00) KDM4ELMNAL3MBTL1TDP1SMN1; SMN2
Meglumine SCHEMBL12195402 1.00 KDM4E (1.00) KDM4ELMNAL3MBTL1TDP1SMN1; SMN2
Meglumine SCHEMBL22641548 1.00 KDM4E (1.00) KDM4ELMNAL3MBTL1TDP1SMN1; SMN2
Meglumine SCHEMBL23363692 1.00 KDM4E (1.00) KDM4ELMNAL3MBTL1TDP1SMN1; SMN2
Meglumine SCHEMBL23106596 1.00 KDM4E (1.00) KDM4ELMNAL3MBTL1TDP1SMN1; SMN2
Meglumine SCHEMBL20836266 1.00 KDM4E (1.00) KDM4ELMNAL3MBTL1TDP1SMN1; SMN2
Meglumine SCHEMBL23363691 1.00 KDM4E (1.00) KDM4ELMNAL3MBTL1TDP1SMN1; SMN2
Meglumine SCHEMBL22562873 1.00 KDM4E (1.00) KDM4ELMNAL3MBTL1TDP1SMN1; SMN2
Meglumine SCHEMBL5584 1.00 KDM4E (1.00) KDM4ELMNAL3MBTL1TDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6258840-B1 ANTITUMOR AGENTS, ANTIINFLAMMATORY AGENTS, ENZYME INHIBITORS OF KINASES COBRA THERAPEUTICS LIMITED (GB) 2001-07-10 US claimed
EP-0912541-A1 ANALOGUES OR DERIVATIVES OF QUERCETIN (PRODRUGS) Cobra Therapeutics Limited (GB) 1999-05-06 EP claimed
WO-1997049693-A1 ANALOGUES OR DERIVATIVES OF QUERCETIN (PRODRUGS) COBRA THERAPEUTICS LIMITED (GB) 1997-12-31 WO claimed
US-5541037-A PHOTOLITHOGRAPHY; FLUORINATED ALKYL POLYETHER AMINE SALT SHIN-ETSU CHEMICAL CO., LTD. (JP) 1996-07-30 US claimed
EP-3386953-B1 CONTRAST AGENTS BRACCO IMAGING SPA (IT) 2020-10-21 EP disclosed
EP-2782921-B1 ORGANIC TUNGSTEN COMPLEXES VANDERBILT CHEMICALS LLC (US) 2018-05-02 EP disclosed
WO-2017098038-A1 CONTRAST AGENTS BRACCO IMAGING SPA (IT) 2017-06-15 WO disclosed
US-20150148311-A1 NON-SYSTEMIC TGR5 AGONISTS ARDELYX INC (US) 2015-05-28 US disclosed
US-8932715-B2 Precipitation stabilising compositions comprising bioactive molecule and at least one cationic and one anionic precipitation stabilizing additives UNIVERSITY OF STRATHCLYDE (GB) 2015-01-13 US disclosed
EP-2794576-A1 NON-SYSTEMIC TGR5 AGONISTS Ardelyx, Inc. (US) 2014-10-29 EP disclosed
EP-2782921-A1 ORGANIC TUNGSTEN COMPLEXES Vanderbilt Chemicals, LLC (US) 2014-10-01 EP disclosed
EP-2099757-B1 SULFOXIMINES AS KINASE INHIBITORS ALLERGAN INC (US) 2014-06-25 EP disclosed
EP-1140901-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2001-10-10 EP disclosed
US-6258840-B1 ANTITUMOR AGENTS, ANTIINFLAMMATORY AGENTS, ENZYME INHIBITORS OF KINASES COBRA THERAPEUTICS LIMITED (GB) 2001-07-10 US disclosed
US-6169206-B1 4-(N,N-DIALKYLAMINO)ANILINE COMPOUNDS USEFUL AS DEVELOPING AGENTS FOR SILVER HALIDE COLOR PHOTOGRAPHY OR AS DYES OR INTERMEDIATES FUJI PHOTO FILM CO., LTD. (JP) 2001-01-02 US disclosed
WO-2000039087-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-07-06 WO disclosed
US-6043006-A 4-(N,N-dialkylamino)aniline compound, photographic processing composition containing the same and color image-forming method FUJI PHOTO FILM CO., LTD. (JP) 2000-03-28 US disclosed
EP-0912541-A1 ANALOGUES OR DERIVATIVES OF QUERCETIN (PRODRUGS) Cobra Therapeutics Limited (GB) 1999-05-06 EP disclosed
WO-1997049693-A1 ANALOGUES OR DERIVATIVES OF QUERCETIN (PRODRUGS) COBRA THERAPEUTICS LIMITED (GB) 1997-12-31 WO disclosed
US-5541037-A PHOTOLITHOGRAPHY; FLUORINATED ALKYL POLYETHER AMINE SALT SHIN-ETSU CHEMICAL CO., LTD. (JP) 1996-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148311-A1 NON-SYSTEMIC TGR5 AGONISTS GLP1R, GPR119, TRHR KDM4E 2830/4885LMNA 2486/4885L3MBTL1 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.